SLS
SELLAS Life Sciences Group, Inc · Healthcare · Biotechnology
$10.38
-14.71% today · -14.50% 1W
Oct 28 close or latest
After hours $10.38 0.00% ·
Next report
Nov 11
In 14 days
estimated date
EPS estimate
−$0.05
−$0.05 to −$0.05 · 1 analysts
Revenue estimate
$0
Track record
7/8 beats
last 8 reports · moved ±3.7% on average
Reports
| Reported | Quarter | EPS est. | EPS | EPS surprise | Revenue | Reaction | Gap | 5 days |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 AMC | 2Q2026 | −$0.04 | −$0.05 | −$0.01 miss | — | +6.5% +6.3 vs SPY | +7.9% | +18.6% |
| Mar 19, 2026 AMC | 4Q2025 | −$0.06 | −$0.05 | +$0.01 beat | — | -8.5% -7.0 vs SPY | +7.7% | -4.8% |
| Nov 12, 2025 AMC | 3Q2025 | −$0.08 | −$0.06 | +$0.02 beat | — | -2.0% -0.3 vs SPY | +0.7% | +2.0% |
| Aug 12, 2025 AMC | −$0.08 | −$0.07 | +$0.01 beat | — | -3.7% -4.1 vs SPY | +0.6% | +5.6% | |
| May 13, 2025 AMC | −$0.11 | −$0.07 | +$0.04 (+36.4%) beat | — | +7.1% +7.0 vs SPY | +4.3% | +37.6% | |
| Mar 20, 2025 AMC | −$0.11 | −$0.08 | +$0.03 (+27.3%) beat | — | -0.8% -0.9 vs SPY | -6.6% | -4.1% | |
| Nov 13, 2024 AMC | −$0.13 | −$0.10 | +$0.03 (+23.1%) beat | — | 0.0% +0.6 vs SPY | +0.8% | -2.4% | |
| Aug 13, 2024 AMC | −$0.17 | −$0.13 | +$0.04 (+23.5%) beat | — | +0.8% +0.5 vs SPY | 0.0% | +10.1% | |
| May 14, 2024 AMC | −$0.16 | −$0.21 | −$0.05 (−31.2%) miss | — | +7.3% +6.1 vs SPY | -1.5% | +3.6% | |
| Mar 28, 2024 AMC | −$0.03 | −$0.25 | −$0.22 miss | — | +5.9% +6.1 vs SPY | +2.0% | +32.7% | |
| Nov 9, 2023 AMC | $0.02 | −$0.33 | −$0.35 miss | — | 0.0% -1.6 vs SPY | -2.2% | +1.1% | |
| Aug 10, 2023 AMC | −$0.35 | −$0.31 | +$0.04 (+11.4%) beat | — | -1.3% -1.2 vs SPY | -0.6% | -9.6% | |
| May 11, 2023 AMC | −$0.29 | −$0.47 | −$0.18 (−62.1%) miss | — | -11.1% -11.0 vs SPY | -0.6% | -0.6% | |
| Mar 16, 2023 AMC | −$0.33 | −$0.43 | −$0.10 (−30.3%) miss | — | -2.2% -1.0 vs SPY | -0.7% | -11.6% | |
| Nov 14, 2022 BMO | −$0.39 | −$0.34 | +$0.05 (+12.8%) beat | — | -44.0% -43.1 vs SPY | -31.6% | -42.9% | |
| Aug 11, 2022 AMC | −$0.37 | −$0.42 | −$0.05 (−13.5%) miss | — | -2.8% -4.5 vs SPY | -2.8% | +4.7% | |
| May 12, 2022 AMC | −$0.42 | −$0.42 | $0.00 (0.0%) in line | — | +10.4% +8.0 vs SPY | -0.8% | +49.4% | |
| Mar 31, 2022 AMC | −$0.41 | −$0.42 | −$0.01 (−2.4%) miss | — | -37.9% -38.1 vs SPY | -36.8% | -43.9% | |
| Nov 12, 2021 BMO | −$0.34 | −$0.45 | −$0.11 (−32.4%) miss | — | -18.5% -19.2 vs SPY | -3.5% | -22.0% | |
| Aug 12, 2021 AMC | −$0.39 | −$0.30 | +$0.09 (+23.1%) beat | — | — | — | — | |
| May 13, 2021 AMC | −$0.36 | −$0.16 | +$0.20 (+55.6%) beat | — | — | — | — | |
| Mar 23, 2021 AMC | −$0.36 | −$0.32 | +$0.04 (+11.1%) beat | — | — | — | — | |
| Nov 13, 2020 AMC | −$0.34 | −$0.53 | −$0.19 (−55.9%) miss | — | — | — | — | |
| Aug 13, 2020 AMC | −$0.64 | −$0.63 | +$0.01 (+1.6%) beat | — | — | — | — |
BMO = before the open, AMC = after the close. Reaction: the first session that could trade on the report (the same day for BMO, the next session for AMC) against the close before it; "vs SPY" subtracts the S&P 500 over the same session. EPS surprise is in dollars, with the percentage only when the estimate is at least $0.10 (near zero, a small beat would show as hundreds of percent). Revenue surprise needs the estimate from before the report, so it starts with the reports Wallsti saw coming.
Analyst estimates
| Period | EPS | Range | vs year ago | 90-day trend | Revisions 30d | Revenue | vs year ago |
|---|---|---|---|---|---|---|---|
| Current quarter · Sep 30, 2026 | −$0.05 (1) | −$0.05 – −$0.05 | +17% | -9.1% | — | — | 0% |
| Next quarter · Dec 31, 2026 | −$0.05 (1) | −$0.05 – −$0.05 | 0% | -9.1% | — | — | 0% |
| Current year · Dec 31, 2026 | −$0.20 (1) | −$0.20 – −$0.20 | +20% | -4.8% | — | — | 0% |
| Next year · Dec 31, 2027 | −$0.10 (2) | −$0.20 – $0.00 | +50% | -33.3% | ▲1 ▼0 | $53.1M | 0% |
Consensus as of Oct 28, 2026. Source: Yahoo Finance analyst estimates; schedule and timing also from Nasdaq's earnings calendar.